NextCell Pharma publish Interim Report 1 2024/2025

January 30, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First Quarter (2024-09-01 to 2024-11-30)

Operating income amounted to 2,864 (4,695) TSEK, of which Cellaviva contributed 2,828 (4,246) TSEK.
Net sales amounted to 2,828 (4,246) TSEK.
Profit/loss after financial items amounted to -8,042 (-9,796) TSEK.
Earnings per share* were -0.11 (-0.28) SEK.
Cash and cash equivalents amounted to 34,123 (40,428) TSEK.
Equity ratio** amounted to 86 (81) percent.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the first quarter of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 30 November 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the first quarter

At the beginning of September, the Company presented new clinical long-term data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results demonstrate the long-term safety and efficacy of the treatment in preserving endogenous insulin production, along with additional health benefits for patients with type 1 diabetes (T1D), such as lower BMI and blood pressure.
At the end of September, the Company announced that the first four children in the 7–11 age group had been treated in the latest phase of the ProTrans-Young study, with an additional four children screened and expected to begin treatment shortly. These developments mark a significant milestone in the study, which is progressing faster than anticipated.
In early October, the Company announced that ProTrans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.
In early November, NextCell Pharma participated in BIO-Europe 2024, one of Europe’s most important partnering conferences in biotechnology and pharmaceutical development, which was attended by Sweden's Minister for Energy and Enterprise and Deputy Prime Minister, Ebba Busch.
At the end of November, QVance, a subsidiary of NextCell Pharma, announced two significant partnerships with bioMérieux Sweden and Royal International.
In late November, the Company announced that Eva Sjökvist Saers was elected as a new board member at the Annual General Meeting.

Significant events after the reporting period

In December, NextCell reported new results from the ProTrans-Repeat study. "The results from the ProTrans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," commented Mathias Svahn, CEO.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on
30th January 2025, 08.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 0+46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For information about Cellaviva, please contact:

Sofie Falk Jansson, CEO

Tel: 08-735 2010

E-mail: info@cellaviva.se

Website: www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige

Twitter: https://www.instagram.com/cellaviva/

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2018-12-05

NextCell strengthens the organization for continued growth

NextCell Pharma AB ("NextCell") hereby announces that the Board has decided to appoint Sofia Fredrikson to CFO in the company. Sofia Fredrikson will take office starting today. Former CFO, Leo Groenewegen, will continue to work for the company in the newly created role of Business Development Manager. Both Sofia Fredrikson and Leo Groenewegen will be part of NextCell's management team. Sofia Fredrikson, born 1983, has been employed by NextCell since November 2018. The Board has now decided to appoint Fredrikson as CFO for the company. Sofia Fredrikson has worked as an authorized accountant

Read more Read more

2018-11-28

NextCell CEO invited speaker at Karolinska Institutet Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the Karolinska Institutet conference “From tissue to motion” - a 10-year anniversary. The conference brings together different research groups within the field of regenerative medicine who will meet with entrepreneurs and life science companies for two days. The scope is to cover the very latest progress of the research in the multidisciplinary fields of regenerative medicine, motion and health.

Read more Read more

2018-11-16

ProTrans trial is approved for high dose treatment in the phase II part

The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Swedish Medical Product Agency has approved the amendment for treatment of patients in the ProTrans-1 trial with high dose of ProTrans in the randomized placebo-controlled part. The ProTrans clinical trial is divided into a dose-scale part where 9 patients were treated with ProTrans during 2018. On October 25th, the Data Safety and Monitoring Board recommended the start of the second part of the trial with the dose that the study team found most appropriate. The safety of ProTrans seem well tolerated, NXTCL

Read more Read more

2018-11-14

NextCell Pharma's clinical trial on the TV3 Diabetes gala

Stem cell company NextCell Pharma AB ("NXTCL") announces that the ongoing clinical trial with ProTrans for the treatment of type 1 diabetes, tonight will be highlighted on the Diabetes Gala. A shorter clip will be shown on the gala and a longer version will be available on ViaPlay, Viafree and on the NXTCL website. The broadcast strats at 20:00.

Read more Read more

2018-11-12

Earlier announced directed share issue to Nordic Tech House AB registered at the Swedish Companies Registrations Office

NextCell Pharma AB ("NextCell") hereby announces that the directed share issue to Nordic Tech House AB (”NTH”) has been registered at the Swedish Companies Registrations Office (Bolagsverket). The newly issued shares are under lock-up. In total, 260 100 shares have been issued at a subscription price of SEK 5.767 per share, equivalent to 2.3 percent of votes and capital in NXTCL. The shares will be settled retrospectively. After the registration at the Swedish Companies Registrations Office, the total amount of shares in NXTCL are 11 486 456 and the share capital is SEK 2 354 723,48. NTH has

Read more Read more

2018-11-09

Publication of annual report 2017/2018

NextCell Pharma AB hereby, on November 9th, 2018, publishes the annual report for the fiscal year 2017/2018. The annual report is available on the company’s website (www.nextcellpharma.com) and Spotlight Stock Market’s website (www.spotlightstockmarket.com).

Read more Read more

2018-11-05

Application for clinical trial submitted to the Medical Products Agency, ProTrans-2.

NextCell Pharma AB ("NXTCL") today announced that a new application to conduct a clinical trial with ProTrans has been submitted to the Swedish Medical Products Agency. The purpose of the study is to evaluate repeated treatment with ProTrans, including patients with type 1 diabetes who participated in the dose escalating part of the original NXTCL trial. The ongoing clinical trial called ProTrans-1, was initiated with a dose escalation phase for 9 patients all followed for 12 months. After their last visit in the study, patients will be asked if they want to participate in a new study where

Read more Read more

2018-11-02

Update regarding targeted new issue to Nordic Tech House

NextCell Pharma (NXTCL), announces today that the Board, with the authorization of the Annual General Meeting of December 5, 2017, has decided to implement a directed new issue of Nordic Tech House AB ("NTH") of a maximum of approximately SEK 1.5 million. The reasons for the deviation from shareholders' pre-emption rights are to fulfil the company's commitment in accordance with an agreement with Nordic Tech House AB, which was concluded to provide the company with new owners of strategic importance. Current decision replaces previous resolutions on directed new issue from March 13, 2018,

Read more Read more